

UNITYPOINT HEALTH - MERITER LABORATORIES
TEST ANNOUNCEMENT
Change in Antibiotic Reporting and Breakpoint Updates

08/20/2024

The antibiotics routinely reported for Gram Negative Rods including *Enterobacteriales* and *Pseudomonas aeruginosa* will change starting 9/3/2024. Breakpoints have also been updated to current CLSI guidelines for some of these organisms. Please note the following:

- Other drugs will be released when resistance is seen in the regularly reported antibiotics.
- Product limitations may delay the resulting of some organism/drug combinations as these results will need to be verified by a different method.
- Fosfomycin changes include:
 - ED urine *E coli* isolates will be reported when both Ampicillin and Cefazolin are resistant.
 - Inpatient urine *E coli* isolates will be reported by request only.

Please see below tables for the antibiotics that will be reported and any breakpoint changes:

<i>Enterobacteriales</i>	New Breakpoints
Ampicillin	
Cefazolin	2(S)/4(I)/8(R)
Cefepime	SDD replacing Intermediate
Cefoxitin	
Cefpodoxime	
Ceftazidime (Under one year of age only)	
Ceftriaxone	
Cefuroxime	
Cefuroxime-Axetil	
Ciprofloxacin	0.25(S)/0.5(I)/1(R)
Gentamicin	2(S)/4(I)/8(R)
Levofloxacin	0.5(S)/1(I)/2(R)
Nitrofurantoin (Urine only)	
Piperacillin/Tazobactam	8(S)/16(SDD)/32(R)
Tobramycin	2(S)/4(I)/8(R)
Trimethoprim/Sulfamethoxazole	
Additional Breakpoint update for drug not routinely reported: Amikacin 4(S)/8(I)/16(R)	

<i>Pseudomonas aeruginosa</i>	New Breakpoints
Cefepime	8(S)/16(I)/32(R)
Ceftazidime (Under one year of age only)	8(S)/16(I)/32(R)
Ciprofloxacin	0.5(S)/1(I)/2(R)
Levofloxacin	1(S)/2(I)/4(R)
Piperacillin/Tazobactam	16(S)/32(I)/64(R)
Tobramycin	1(S)/2(I)/4(R)
Additional Breakpoint update for drug not routinely reported: Meropenem 2(S)/4(I)/8(R)	

If you have any questions, please call the UnityPoint Health - Meriter Laboratories Client Services Department at 608-417-6529 or 1-800-236-0465.